vs
QuidelOrtho Corp（QDEL）与BOSTON BEER CO INC（SAM）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是BOSTON BEER CO INC的1.8倍（$699.9M vs $385.7M），BOSTON BEER CO INC净利率更高（-5.8% vs -104.7%，领先98.9%），QuidelOrtho Corp同比增速更快（-3.7% vs -4.1%），BOSTON BEER CO INC自由现金流更多（$22.1M vs $-94.7M），过去两年QuidelOrtho Corp的营收复合增速更高（-2.9% vs -4.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
波士顿啤酒公司是美国知名酿酒企业，1984年由吉姆·科赫与朗达·卡尔曼联合创立。旗下首款产品以美国开国元勋、独立运动先驱塞缪尔·亚当斯命名，后续陆续推出多个自有品牌，2019年正式完成与角鲨头酿酒厂的合并，是北美精酿啤酒行业的核心参与者之一。
QDEL vs SAM — 直观对比
营收规模更大
QDEL
是对方的1.8倍
$385.7M
营收增速更快
QDEL
高出0.4%
-4.1%
净利率更高
SAM
高出98.9%
-104.7%
自由现金流更多
SAM
多$116.8M
$-94.7M
两年增速更快
QDEL
近两年复合增速
-4.9%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $385.7M |
| 净利润 | $-733.0M | $-22.5M |
| 毛利率 | — | 43.5% |
| 营业利润率 | -100.7% | -8.6% |
| 净利率 | -104.7% | -5.8% |
| 营收同比 | -3.7% | -4.1% |
| 净利润同比 | -3583.4% | 41.9% |
| 每股收益（稀释后） | $-10.78 | $-1.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELSAM
| Q4 25 | — | $385.7M | ||
| Q3 25 | $699.9M | $537.5M | ||
| Q2 25 | $613.9M | $587.9M | ||
| Q1 25 | $692.8M | $453.9M | ||
| Q4 24 | $707.8M | $402.3M | ||
| Q3 24 | $727.1M | $605.5M | ||
| Q2 24 | $637.0M | $579.1M | ||
| Q1 24 | $711.0M | $426.1M |
净利润QDELSAM
| Q4 25 | — | $-22.5M | ||
| Q3 25 | $-733.0M | $46.2M | ||
| Q2 25 | $-255.4M | $60.4M | ||
| Q1 25 | $-12.7M | $24.4M | ||
| Q4 24 | $-178.4M | $-38.8M | ||
| Q3 24 | $-19.9M | $33.5M | ||
| Q2 24 | $-147.7M | $52.3M | ||
| Q1 24 | $-1.7B | $12.6M |
毛利率QDELSAM
| Q4 25 | — | 43.5% | ||
| Q3 25 | — | 50.8% | ||
| Q2 25 | — | 49.8% | ||
| Q1 25 | — | 48.3% | ||
| Q4 24 | — | 39.9% | ||
| Q3 24 | — | 46.3% | ||
| Q2 24 | — | 46.0% | ||
| Q1 24 | — | 43.7% |
营业利润率QDELSAM
| Q4 25 | — | -8.6% | ||
| Q3 25 | -100.7% | 11.5% | ||
| Q2 25 | -29.4% | 14.0% | ||
| Q1 25 | 4.7% | 7.4% | ||
| Q4 24 | -14.2% | -13.9% | ||
| Q3 24 | 2.1% | 7.6% | ||
| Q2 24 | -18.4% | 12.2% | ||
| Q1 24 | -247.3% | 3.6% |
净利率QDELSAM
| Q4 25 | — | -5.8% | ||
| Q3 25 | -104.7% | 8.6% | ||
| Q2 25 | -41.6% | 10.3% | ||
| Q1 25 | -1.8% | 5.4% | ||
| Q4 24 | -25.2% | -9.6% | ||
| Q3 24 | -2.7% | 5.5% | ||
| Q2 24 | -23.2% | 9.0% | ||
| Q1 24 | -239.9% | 3.0% |
每股收益（稀释后）QDELSAM
| Q4 25 | — | $-1.97 | ||
| Q3 25 | $-10.78 | $4.25 | ||
| Q2 25 | $-3.77 | $5.45 | ||
| Q1 25 | $-0.19 | $2.16 | ||
| Q4 24 | $-2.54 | $-3.23 | ||
| Q3 24 | $-0.30 | $2.86 | ||
| Q2 24 | $-2.20 | $4.39 | ||
| Q1 24 | $-25.50 | $1.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $223.4M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $846.3M |
| 总资产 | $5.7B | $1.2B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资QDELSAM
| Q4 25 | — | $223.4M | ||
| Q3 25 | $98.1M | $250.5M | ||
| Q2 25 | $151.7M | $212.4M | ||
| Q1 25 | $127.1M | $152.5M | ||
| Q4 24 | $98.3M | $211.8M | ||
| Q3 24 | $143.7M | $255.6M | ||
| Q2 24 | $107.0M | $219.3M | ||
| Q1 24 | $78.5M | $205.4M |
总债务QDELSAM
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
股东权益QDELSAM
| Q4 25 | — | $846.3M | ||
| Q3 25 | $2.0B | $911.0M | ||
| Q2 25 | $2.8B | $912.3M | ||
| Q1 25 | $3.0B | $897.0M | ||
| Q4 24 | $3.0B | $916.2M | ||
| Q3 24 | $3.2B | $1.0B | ||
| Q2 24 | $3.2B | $1.0B | ||
| Q1 24 | $3.3B | $1.0B |
总资产QDELSAM
| Q4 25 | — | $1.2B | ||
| Q3 25 | $5.7B | $1.2B | ||
| Q2 25 | $6.4B | $1.3B | ||
| Q1 25 | $6.5B | $1.2B | ||
| Q4 24 | $6.4B | $1.3B | ||
| Q3 24 | $6.8B | $1.4B | ||
| Q2 24 | $6.7B | $1.4B | ||
| Q1 24 | $6.7B | $1.4B |
负债/权益比QDELSAM
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $39.9M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | $22.1M |
| 自由现金流率自由现金流/营收 | -13.5% | 5.7% |
| 资本支出强度资本支出/营收 | 7.0% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-153.1M | $215.6M |
8季度趋势，按日历期对齐
经营现金流QDELSAM
| Q4 25 | — | $39.9M | ||
| Q3 25 | $-45.5M | $101.8M | ||
| Q2 25 | $-46.8M | $126.5M | ||
| Q1 25 | $65.6M | $1.9M | ||
| Q4 24 | $63.7M | $41.9M | ||
| Q3 24 | $117.9M | $115.9M | ||
| Q2 24 | $-97.9M | $96.0M | ||
| Q1 24 | $-700.0K | $-4.9M |
自由现金流QDELSAM
| Q4 25 | — | $22.1M | ||
| Q3 25 | $-94.7M | $89.2M | ||
| Q2 25 | $-84.3M | $112.2M | ||
| Q1 25 | $9.4M | $-8.0M | ||
| Q4 24 | $16.5M | $18.4M | ||
| Q3 24 | $71.4M | $99.2M | ||
| Q2 24 | $-133.2M | $75.6M | ||
| Q1 24 | $-66.8M | $-20.6M |
自由现金流率QDELSAM
| Q4 25 | — | 5.7% | ||
| Q3 25 | -13.5% | 16.6% | ||
| Q2 25 | -13.7% | 19.1% | ||
| Q1 25 | 1.4% | -1.8% | ||
| Q4 24 | 2.3% | 4.6% | ||
| Q3 24 | 9.8% | 16.4% | ||
| Q2 24 | -20.9% | 13.1% | ||
| Q1 24 | -9.4% | -4.8% |
资本支出强度QDELSAM
| Q4 25 | — | 4.6% | ||
| Q3 25 | 7.0% | 2.3% | ||
| Q2 25 | 6.1% | 2.4% | ||
| Q1 25 | 8.1% | 2.2% | ||
| Q4 24 | 6.7% | 5.8% | ||
| Q3 24 | 6.4% | 2.8% | ||
| Q2 24 | 5.5% | 3.5% | ||
| Q1 24 | 9.3% | 3.7% |
现金转化率QDELSAM
| Q4 25 | — | — | ||
| Q3 25 | — | 2.21× | ||
| Q2 25 | — | 2.09× | ||
| Q1 25 | — | 0.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.46× | ||
| Q2 24 | — | 1.83× | ||
| Q1 24 | — | -0.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
SAM
暂无分部数据
